Literature DB >> 30013671

Elucidating feed-forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome.

Diana A Fisler1, Dhiraj Sikaria1, John M Yavorski1, Yaping N Tu1, George Blanck1,2.   

Abstract

Overstimulation of pro-proliferative pathways and high level expression of pro-proliferative transcription factors (TFs) can lead to apoptosis. This is likely due to TF binding sites for pro-proliferative TFs common to pro-proliferative and pro-apoptosis-effector genes. Certain clinical datasets have indicated that molecular markers associated with higher proliferation rates lead to improved outcomes for patients with cancer. These observations have been extensively assessed on a general basis, however there has been little work dissecting feed-forward apoptosis signaling pathways that may represent specific distinctions between a pro-proliferative mechanism and a pro-apoptotic mechanism in samples from patients with cancer. Using The Cancer Genome Atlas datasets and bioinformatic approaches, the present study reports that higher FOS expression levels, along with higher FOS target apoptosis-effector gene expression, is associated with an increased survival, while higher POU2F1 expression is associated with a reduced survival (average difference of 25.9 months survival). In summary, in the datasets examined FOS represents an apoptosis-driver and high POU2F1 represents a driver mechanism for cancer development.

Entities:  

Keywords:  FOS; GZMA; UQCRC2; apoptosis-driver; apoptosis-effector genes; breast cancer; cancer-driver

Year:  2018        PMID: 30013671      PMCID: PMC6036554          DOI: 10.3892/ol.2018.8957

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

Review 1.  Granzyme A activates another way to die.

Authors:  Judy Lieberman
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  E2F-1 functions in mice to promote apoptosis and suppress proliferation.

Authors:  S J Field; F Y Tsai; F Kuo; A M Zubiaga; W G Kaelin; D M Livingston; S H Orkin; M E Greenberg
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

3.  Tumor induction and tissue atrophy in mice lacking E2F-1.

Authors:  L Yamasaki; T Jacks; R Bronson; E Goillot; E Harlow; N J Dyson
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

4.  Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma.

Authors:  Dhiraj Sikaria; Yaping N Tu; Diana A Fisler; James A Mauro; George Blanck
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-05       Impact factor: 4.553

5.  The E2F transcription factor activates a replication-dependent human H2A gene in early S phase of the cell cycle.

Authors:  F Oswald; T Dobner; M Lipp
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

6.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN.

Authors:  T Teitz; T Wei; M B Valentine; E F Vanin; J Grenet; V A Valentine; F G Behm; A T Look; J M Lahti; V J Kidd
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

7.  TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma.

Authors:  John M Yavorski; George Blanck
Journal:  Cell Cycle       Date:  2016-06-29       Impact factor: 4.534

8.  The nuclear protein UHRF2 is a direct target of the transcription factor E2F1 in the induction of apoptosis.

Authors:  Huarui Lu; Timothy C Hallstrom
Journal:  J Biol Chem       Date:  2013-07-05       Impact factor: 5.157

9.  Stratifying melanoma and breast cancer TCGA datasets on the basis of the CNV of transcription factor binding sites common to proliferation- and apoptosis-effector genes.

Authors:  James A Mauro; John M Yavorski; George Blanck
Journal:  Gene       Date:  2017-02-28       Impact factor: 3.688

10.  Smoking correlates with increased cytoskeletal protein-related coding region mutations in the lung and head and neck datasets of the cancer genome atlas.

Authors:  John M Yavorski; George Blanck
Journal:  Physiol Rep       Date:  2016-12
View more
  9 in total

1.  Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma.

Authors:  Boris I Chobrutskiy; Michelle Yeagley; Price Tipping; Saif Zaman; Andrea Diviney; Dhruv N Patel; Shayan Falasiri; Vladimir N Uversky; George Blanck
Journal:  Oncogene       Date:  2019-11-18       Impact factor: 9.867

2.  Combinatorial Treatment with PARP-1 Inhibitors and Cisplatin Attenuates Cervical Cancer Growth through Fos-Driven Changes in Gene Expression.

Authors:  Rebecca Gupte; Ken Y Lin; Tulip Nandu; Jayanthi S Lea; W Lee Kraus
Journal:  Mol Cancer Res       Date:  2022-08-05       Impact factor: 6.333

3.  Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection.

Authors:  Arzu Cakir; Melisa Tuncer; Hilal Taymaz-Nikerel; Ozlem Ulucan
Journal:  Pharmacogenomics J       Date:  2021-06-21       Impact factor: 3.550

4.  Retinoblastoma tumor cell proliferation is negatively associated with an immune gene expression signature and increased immune cells.

Authors:  Aaron L Sarver; Chencheng Xie; Megan J Riddle; Colleen L Forster; Xiaohong Wang; Huarui Lu; Wyatt Wagner; Jakub Tolar; Timothy C Hallstrom
Journal:  Lab Invest       Date:  2021-03-03       Impact factor: 5.662

5.  Identification of oxytocin-related lncRNAs and assessment of their expression in breast cancer.

Authors:  Sepehr Behtaji; Soudeh Ghafouri-Fard; Arezou Sayad; Ali Sattari; Mathieu Rederstorff; Mohammad Taheri
Journal:  Sci Rep       Date:  2021-03-19       Impact factor: 4.379

6.  An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia.

Authors:  Andrea Diviney; Boris I Chobrutskiy; Saif Zaman; George Blanck
Journal:  Cancer Cell Int       Date:  2019-03-27       Impact factor: 5.722

7.  Prognostic role of EGR1 in breast cancer: a systematic review.

Authors:  Subbroto Kumar Saha; S M Riazul Islam; Tripti Saha; Afsana Nishat; Polash Kumar Biswas; Minchan Gil; Lewis Nkenyereye; Shaker El-Sappagh; Md Saiful Islam; Ssang-Goo Cho
Journal:  BMB Rep       Date:  2021-10       Impact factor: 4.778

8.  The initial expression alterations occurring to transcription factors during the formation of breast cancer: Evidence from bioinformatics.

Authors:  Xingxing Dong; Yalong Yang; Gaoran Xu; Zelin Tian; Qian Yang; Yan Gong; Gaosong Wu
Journal:  Cancer Med       Date:  2022-01-17       Impact factor: 4.452

9.  Oct1/Pou2f1 is selectively required for colon regeneration and regulates colon malignancy.

Authors:  Karina Vázquez-Arreguín; Claire Bensard; John C Schell; Eric Swanson; Xinjian Chen; Jared Rutter; Dean Tantin
Journal:  PLoS Genet       Date:  2019-05-06       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.